


RealRate

PHARMACEUTICAL 2017

Neurotrope Inc. Rank 62 of 292







RealRate

Neurotrope Inc. Rank 62 of 292

The relative strengths and weaknesses of Neurotrope Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neurotrope Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Neurotrope Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 195%, being 192% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	25,912
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,363
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	3,893
Other Liabilities	0
Other Net Income	8.4
Other Revenues	0
Property and Equipment	55
Research and Development	5,604
Selling, General and Administrative Expense	3,436

Output Variable	Value in 1000 USD
Assets	25,967
Liabilities	2,363
Expenses	12,933
Revenues	0
Stockholders Equity	23,605
Net Income	-12,924
Comprehensive Net Income	-12,924
Economic Capital Ratio	195%

